Skip to content Skip to footer

States to Receive Fewer Vaccines Than Promised as Trump Boasts About Rollout

Several states have been told to expect up to 40 percent in cuts to expected vaccine distribution numbers.

Technicians measure doses of the Pfizer vaccine for COVID-19 at the Virginia Hospital Center on December 16, 2020, in Arlington, Virginia.

As President Donald Trump praises his administration’s handling and delivery of several thousand doses of coronavirus vaccines, several governors across the country have expressed misgivings over what will happen next week, after federal officials told them to expect cuts of up to 40 percent in anticipated dosage numbers.

Hundreds of thousands of Americans, mostly health care workers, have been vaccinated as of Friday.

“The Vaccine and the Vaccine rollout are getting the best of reviews. Moving along really well. Get those ‘shots’ everyone!” Trump tweeted on Thursday.

But governors and health leaders have expressed worries over distribution of the Pfizer-BioNTech version of the vaccine, which was sent out this week, after federal officials told them that the shipments being sent out next week would be significantly fewer than originally expected.

The federal government gave state leaders few details about why shipments would be down. Two Trump officials, speaking to The Associated Press on the matter, explained that the delivery reduction was due to changes to schedules and misunderstandings about supply changes.

Gov. Jay Inslee (D-Washington) blasted the administration’s handling of the rollout of vaccines, as many states are set to see reductions in expected dosage rates between 25 percent to 40 percent.

“This is disruptive and frustrating,” Inslee wrote in a tweet. “We need accurate, predictable numbers to plan and ensure on-the-ground success.”

Washington State was told to expect cuts of the Pfizer vaccine by as much as 40 percent next week. The same rate cut is expected in California, which has been hit hard by the pandemic in recent weeks. Missouri may also see a cut in its vaccine numbers as high as 30 percent.

For its own part, Pfizer has said that nothing on its end has changed, as far as production and rollout.

“Pfizer has not had any production issues with our COVID-19 vaccine, and no shipments containing the vaccine are on hold or delayed,” Pfizer spokesman Eamonn Nolan said.

The pace of vaccination may increase next week anyway if the Moderna version of the vaccine gets federal authorization. The Food and Drug Administration (FDA) is expected to grant approval for the vaccine on Friday.

Beyond the latest snafus, Trump’s glowing praise of his administration’s efforts to roll out vaccines for coronavirus may be premature for another reason: Most Americans will not be able to get a vaccine for quite some time. Even with the Moderna version of the vaccine included, only 150 million Americans — less than half the country’s population — will be able to receive a vaccine by June, due in large part to the administration’s failure to purchase enough dosages of both vaccines earlier this year.

For the vaccines to be effective, most experts agree, at least 70 percent of the population has to be inoculated.

Since the start of the pandemic, more than 17.2 million Americans have tested positive for the virus. As of Friday morning, more than 310,000 have died due to coronavirus.